CGRP mAbs show additive value with onabotulinumtoxinA therapy for chronic migraine

Researchers from Montefiore and Columbia University Medical Centers, New York, USA, have reported that calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) approved for use in chronic migraine appear to be an effective and well-tolerated treatment addition for patients already on onabotulinumtoxinA.